Literature DB >> 18651015

Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment with prednisone, imatinib mesylate and hydroxyurea.

Joseph H Butterfield1, Scott W Sharkey.   

Abstract

Uncontrolled hypereosinophilic syndrome is frequently associated with cardiovascular consequences that cause significant morbidity and mortality. The present article reports on a patient with hypereosinophilic syndrome in whom recurrent, recalcitrant coronary artery spasm and associated cardiac arrest were the predominant cardiac manifestations. No valvular abnormalities, evidence of mural thrombi or other cardiac findings commonly associated with hypereosinophilic syndrome were detected, and cardiac function remained normal. The serum tryptase level was normal, cysteine-rich hydrophobic domain 2 (CHIC2) deletion analysis of bone marrow cells was negative and no evidence of mastocytosis or other hematological disorder was found in the bone marrow. To allow for the reduction of prednisone, interferon-alpha-2b was added to the patient's program, but caused aggravation of chest pain and was discontinued. However, a combination of reduced prednisone dosage, imatinib mesylate and hydroxyurea successfully controlled the eosinophilia, and thereafter, episodes of coronary artery spasm did not recur. The clinical features of the present case suggest that, in some patients, hypereosinophilia may manifest as resistant coronary artery spasm and that aggressive control of eosinophilia is necessary.

Entities:  

Keywords:  Coronary artery spasm; Hydroxyurea; Idiopathic hypereosinophilic syndrome; Imatinib mesylate

Year:  2006        PMID: 18651015      PMCID: PMC2274835     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  38 in total

1.  Increased adventitial mast cells in a patient with coronary spasm.

Authors:  M B Forman; J A Oates; D Robertson; R M Robertson; L J Roberts; R Virmani
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

2.  A case of variant angina associated with eosinophilia.

Authors:  Y Hirakawa; S Koyanagi; T Matsumoto; A Takeshita; M Nakamura
Journal:  Am J Med       Date:  1989-10       Impact factor: 4.965

3.  Cardiovascular features of 11 patients with eosinophilic endomyocardial disease.

Authors:  J Davies; C J Spry; R Sapsford; E G Olsen; G de Perez; C M Oakley; J F Goodwin
Journal:  Q J Med       Date:  1983

4.  Toxic effects of human eosinophil products on isolated rat heart cells in vitro.

Authors:  P C Tai; D J Hayes; J B Clark; C J Spry
Journal:  Biochem J       Date:  1982-04-15       Impact factor: 3.857

5.  Hypereosinophilic heart disease.

Authors:  J Cameron; D J Radford; J Howell; M F O'Brien
Journal:  Med J Aust       Date:  1985-10-28       Impact factor: 7.738

6.  Persisting hypereosinophilia and myocardial activity in the fibrotic stage of endomyocardial disease.

Authors:  A Frustaci; A K Abdulla; G Possati; U Manzoli
Journal:  Chest       Date:  1989-09       Impact factor: 9.410

7.  Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease. An endomyocardial biopsy study.

Authors:  M Sekiguchi; Z X Yu; M Take; M Hiroe; K Hirosawa; T Shirai; T Ishide; T Takahashi
Journal:  Jpn Circ J       Date:  1984-12

Review 8.  Eosinophilic disorders affecting the myocardium and endocardium: a review.

Authors:  C J Spry; M Take; P C Tai
Journal:  Heart Vessels Suppl       Date:  1985

9.  Mitral annuloplasty in endomyocardial fibrosis: an alternative to valve replacement.

Authors:  A E Wood; D Boyle; M D O'Hara; J Cleland
Journal:  Ann Thorac Surg       Date:  1982-10       Impact factor: 4.330

10.  Activation of platelets by eosinophil granule proteins.

Authors:  M S Rohrbach; C L Wheatley; N R Slifman; G J Gleich
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  1 in total

1.  Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Neelam H Shah; Thomas R Schneider; Doreen DeFaria Yeh; Katherine N Cahill; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2016-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.